U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07392281) titled 'Efficacy and Mechanisms of Macitentan for Non-Coronary Obstructive Angina' on Jan. 22.
Brief Summary: Angina with non-obstructive coronary arteries (ANOCA) is highly prevalent, impairing quality of life and independently associated with cardiovascular events, yet effective treatments are lacking. The endothelin-1 (ET-1)-endothelin receptor (ETR) system is pivotal in ANOCA pathogenesis. Preclinical studies show that ETR blockade or pericyte-specific knockout of ETA receptor improves coronary microcirculatory function in models of myocardial ischemia-reperfusion and diabetes. Clinical evidence indicates ETR antagonists can enhance micr...